We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Sulfinpyrazone: Risk for Renal Insufficiency-Reply

Joseph L. Blackshear, MD; M. Thomas Stillman, MD; Morris Davidman, MD
Arch Intern Med. 1984;144(3):648-649. doi:10.1001/archinte.1984.00350150262055.
Text Size: A A A
Published online


In Reply.  —Boelaert et al have reported a renal antiprostaglandin action of sulfinpyrazone and demonstrated clinically significant adverse effects on renal function from the agent.1,2 These observations supplement data indicating that the antiplatelet activity of sulfinpyrazone is due to its inhibitory effect on platelet cyclo-oxygenase.3,4 Clearly, sulfinpyrazone belongs in the same category as nonsteroidal anti-inflammatory drugs in its ability to precipitate renal insufficiency, but it deserves special mention for two reasons: (1) because sulfinpyrazone is not classified as an anti-inflammatory agent, its ability to produce renal insufficiency is likely to be overlooked, and (2) because sulfinpyrazone's two principle uses are as an antiplatelet agent in atherosclerotic disease or as a uricosuric agent in gout, it is likely to be prescribed in precisely those patients with the underlying risk factors we identified.5The frequency with which renal deterioration occurred from sulfinpyrazone in patients with identifiable risk is illustrated


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.